JNJJohnson & Johnson
JNJ
Johnson & Johnson48,647
Mkt Cap
$555.59BVolume
13.07M52W High
$251.7152W Low
$149.04PE Ratio
26.69JNJ Fundamentals
Price
$225.33Prev Close
$230.80Open
$231.2350D MA
$232.75Beta
0.05Avg. Volume
7.63MEPS (Annual)
$11.03P/B
6.84Rev/Employee
$668,877.84$533,647.35
RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment...
PR Newswire
New TECVAYLI (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
New TECVAYLI (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma New TECVAYLI (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma PR Newswire...
PR Newswire
FDA approves label expansion, cementing TREMFYA as the only IL23 inhibitor proven to help stop further joint damage
FDA approves label expansion, cementing TREMFYA as the only IL23 inhibitor proven to help stop further joint damage FDA approves label expansion, cementing TREMFYA as the only IL23 inhibitor proven to help stop further joint damage PR Newswire HORSHAM, Pa., May 28, 2026 TREMFYA showed significant...
PR Newswire
Is Johnson & Johnson (JNJ) a Buy as Wall Street Analysts Look Optimistic?
The average brokerage recommendation (ABR) for Johnson & Johnson (JNJ) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Zacks
J&J Stock Gains Nearly 12% Year to Date: Buy, Sell or Hold Now?
JNJ is up nearly 12% YTD as strong oncology drug growth, MedTech demand and pipeline advances help offset Stelara patent-loss pressure.
Zacks
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 15th to review second-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Ryan Koors...
Business Wire
BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst
Black Diamond is expanding silevertinib into glioblastoma, adding long-term CNS-driven optionality while NSCLC remains the nearer-term focus.
Zacks
Black Diamond Stock Outlook After Q1 Beat and Cash Runway
BDTX's Q1 beat and cash runway into 2028 keep focus on silevertinib's clinical durability, CNS profile and pivotal path.
Zacks
BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to Know
Black Diamond's May 2026 silevertinib update showed steady NSCLC response rates, CNS activity and dose progress, but durability data remain early.
Zacks
<
1
2
...
>
Compact View
Not available
Not available
Advertisement|Remove ads.
Latest JNJ News
ViewJNJ Reports Promising Survival Data From CHRYSALIS-2 Lung Cancer Study
Stocktwits
RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
PR Newswire
New TECVAYLI (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
PR Newswire
Advertisement|Remove ads.